



## Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference

November 8, 2023

SAN DIEGO, Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies London Healthcare Conference on Tuesday November 14, 2023 at 3:00 p.m. Greenwich Mean Time (10:00 a.m. Eastern Time) in London. Kevin Gorman, Chief Executive Officer, and additional members of Neurocrine management will present at the conference.



The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at [www.neurocrine.com](http://www.neurocrine.com). A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

### **About Neurocrine Biosciences**

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, Parkinson's disease, endometriosis\* and uterine fibroids\*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit [neurocrine.com](http://neurocrine.com), and follow the company on [LinkedIn](#), [X](#) (formerly Twitter) and [Facebook](#). (\*in collaboration with AbbVie)

NEUROCRINE BIOSCIENCES and NEUROCRINE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.

View original content to download multimedia: <https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-jefferies-london-healthcare-conference-301982290.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Tony Jewell (Media), 858-617-7578, [media@neurocrine.com](mailto:media@neurocrine.com); Todd Tushla (Investors), 858-617-7143, [ir@neurocrine.com](mailto:ir@neurocrine.com)